Kenneth G Saag MD, MSc
1
, Donato Agnusdei MD
2
, Didier Hans PhD
3
, Lynn A Kohlmeier
MD
4
, Kelly D Krohn MD
5
, Edward S Leib MD
6
, Edmund J MacLaughlin MD
7
, Jahangir Alam
MS
2
, Christine Simonelli MD
8
, Kathleen A Taylor PhD
5
, Robert Marcus MD
9
1
Department of Medicine, Division of Rheumatology, University of Alabama at Birmingham,
Birmingham, United States
2
BMJ Platform Team, Eli Lilly and Company, Indianapolis, United States
3
Bone and Joint Department, Center of Bone Diseases, Lausanne University Hospital, Lausanne,
Switzerland
4
Department of Endocrinology, Spokane Osteoporosis, Spokane, United States
5
Lilly USA, Indianapolis, United States
6
Department of Medicine, University of Vermont College of Medicine, Burlington, United States
7
Edmund J. MacLaughlin, MD, LLC, Cambridge, United States
8
HealthEast Osteoporosis Care, St. Paul, United States
9
Department of Medicine, Stanford University, Stanford, United States
!" #$"%
Kenneth G. Saag, MD, MSc
University of Alabama at Birmingham, FOT 820
1530 Third Avenue South
Birmingham, AL 35294;3408
Telephone: (205) 996;9784
Fax: 205;975;6859
E;mail: ksaag@uab.edu
&’ (% glucocorticoid;induced osteoporosis, GIO, TBS, BMD, teriparatide, alendronate
)!!)!)*+, for primary study: NCT00051558
Funded by Eli Lilly and Company and/or one of its wholly;owned subsidiaries (Lilly)
Full Length Arthritis & Rheumatology
DOI 10.1002/art.39726
This article has been accepted for publication and undergone full peer review but has not been
through the copyediting, typesetting, pagination and proofreading process which may lead to
differences between this version and the Version of Record. Please cite this article as an
‘Accepted Article’, doi: 10.1002/art.39726
© 2016 American College of Rheumatology
Received: Nov 05, 2015; Revised: Mar 28, 2016; Accepted: Apr 14, 2016
This article is protected by copyright. All rights reserved.